{"id":"ddac-cp-olaparib","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Nausea"},{"rate":"15-25%","effect":"Vomiting"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PARP, ddAC-CP-Olaparib prevents cancer cells from repairing their DNA, leading to cell death. This mechanism is particularly effective in cancers with BRCA1 or BRCA2 mutations, which are already defective in DNA repair. As a result, ddAC-CP-Olaparib is often used in combination with other therapies to enhance its effectiveness.","oneSentence":"ddAC-CP-Olaparib is a PARP inhibitor that works by blocking the enzyme PARP, which is involved in DNA repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:48.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced ovarian cancer with BRCA1 or BRCA2 mutations"},{"name":"Advanced breast cancer with BRCA1 or BRCA2 mutations"}]},"trialDetails":[{"nctId":"NCT02810743","phase":"PHASE3","title":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-01-25","conditions":"Breast Cancer","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ddAC-CP-Olaparib","genericName":"ddAC-CP-Olaparib","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ddAC-CP-Olaparib is a small molecule inhibitor of PARP 1, 2, and 3, used in the treatment of breast cancer. It is part of a clinical trial (NCT02810743) aimed at improving the cure rate of high-risk BRCA1-like breast cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}